876310-02-0 Usage
Uses
Used in Pharmaceutical Industry:
(E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide is used as a potential therapeutic agent for various medical conditions due to its complex structure and the presence of multiple functional groups. Its specific application reason would depend on the results of further research and analysis.
Used in Biochemical Research:
In the field of biochemistry, (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide may be utilized as a research tool to study the interactions between different biomolecules and its potential as a modulator of specific biological pathways.
Used in Materials Science:
(E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide could be explored for its potential applications in materials science, such as the development of new materials with unique properties or the enhancement of existing materials through chemical modifications.
Check Digit Verification of cas no
The CAS Registry Mumber 876310-02-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,6,3,1 and 0 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 876310-02:
(8*8)+(7*7)+(6*6)+(5*3)+(4*1)+(3*0)+(2*0)+(1*2)=170
170 % 10 = 0
So 876310-02-0 is a valid CAS Registry Number.
876310-02-0Relevant articles and documents
Novel preparation method of epidermal growth factor receptor (EGFR) inhibitor neratinib
-
Paragraph 0030; 0031, (2016/11/21)
The invention relates to a preparation method of an epidermal growth factor receptor (EGFR) inhibitor neratinib. The method is characterized in that 6-[(E)-4-(dimethylamino)-2-butenylamido]-7-ethoxy-4-chloro-3-quinolylmethylnitrile (I) continuously reacts with 2-chloro-3-aminophenol (II) and dichloromethylpyridine hydrochloride (III) to temporarily obtain an intermediate (E)-N-{4-[3-chloro-4-hydroxyanilino]3-cyno-5-ethoxy-6-quinolyl}-4-dimethylamino-2-butenylamide (IV) in order to finally obtain neratinib. The preparation method adopts a continuous reaction process, and dichloromethylpyridine hydrochloride (III) is a catalyst in the first stage of the continuous reaction and is a reaction reagent in the second stage of the continuous reaction, so the method has the advantages of simple and easily available raw materials, high yield, mild reaction conditions, extremely small amount of a generated waste liquid, and high facilitation of industrial production of the above raw medicine.